LMOD1 Exerts a Tumor-Suppressive Role in Breast Cancer by Restraining the JAK2/STAT3 Pathway

Xiansong Fang1, Xiaoyun Wen2, Ya Hou3

  • 1Department of Blood transfusion, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China.

Insights

Leiomodin 1 (LMOD1) acts as a tumor suppressor in breast cancer by inhibiting cell proliferation, migration, and fatty acid synthesis. Its effects are linked to the suppression of the JAK2/STAT3 pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer significantly impacts women's health.
  • Identifying novel therapeutic targets and understanding gene functions are crucial.

Purpose of the Study:

  • To screen differentially expressed genes (DEGs) in breast cancer.
  • To elucidate the biological functions and mechanisms of Leiomodin 1 (LMOD1) in breast cancer.

Main Methods:

  • Bioinformatics analysis of gene expression datasets (GSE22820, GSE29431) to identify common DEGs and pivotal genes.
  • Functional assays to assess the impact of LMOD1 overexpression on breast cancer cell phenotypes.
  • Investigation of LMOD1's role in fatty acid synthesis and the JAK2/STAT3 pathway using cell lines and colivelin (a STAT3 activator).

Main Results:

  • Identified 208 common DEGs and 5 pivotal genes, with 5 focal genes downregulated in breast cancer.
  • LMOD1 overexpression suppressed breast cancer cell proliferation, migration, and invasion.
  • LMOD1 overexpression inhibited fatty acid synthesis and was associated with reduced JAK2/STAT3 pathway activation.

Conclusions:

  • LMOD1 functions as a tumor suppressor in breast cancer.
  • LMOD1 impedes malignant phenotypes and fatty acid synthesis, partly through the JAK2/STAT3 pathway.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K